BIOCON - Swing Trade Analysis with AI Signals
Back to List📊 Swing Trade Rating: 3.4
| Stock Code | BIOCON | Market Cap | 67,414 Cr. | Current Price | 416 ₹ | High / Low | 440 ₹ |
| Stock P/E | 283 | Book Value | 167 ₹ | Dividend Yield | 0.12 % | ROCE | 1.92 % |
| ROE | 1.24 % | Face Value | 5.00 ₹ | DMA 50 | 403 ₹ | DMA 200 | 382 ₹ |
| Chg in FII Hold | 0.13 % | Chg in DII Hold | 2.34 % | PAT Qtr | 67.3 Cr. | PAT Prev Qtr | 111 Cr. |
| RSI | 53.9 | MACD | 3.44 | Volume | 18,94,947 | Avg Vol 1Wk | 22,94,949 |
| Low price | 331 ₹ | High price | 440 ₹ | PEG Ratio | 1.65 | Debt to equity | 0.04 |
| 52w Index | 77.4 % | Qtr Profit Var | 218 % | EPS | 0.23 ₹ | Industry PE | 32.5 |
BIOCON presents weak fundamentals for swing trading despite short-term technical support. The company’s profitability ratios are very low (ROCE 1.92%, ROE 1.24%), and EPS is only 0.23 ₹, while the P/E ratio of 283 is extremely high compared to the industry average of 32.5. Technical indicators show neutral momentum — RSI at 53.9 is stable, and MACD at 3.44 suggests mild bullishness. Quarterly PAT declined (111 Cr. → 67.3 Cr.), raising concerns. However, low debt-to-equity (0.04) and institutional support (DII holding +2.34%) provide some positives. Overall, BIOCON is risky for swing trading due to stretched valuations and weak profitability.
Optimal Entry Price: 400–405 ₹ (near DMA 50 support)
Exit Strategy: If already holding, consider exiting near 430–440 ₹ resistance or if RSI approaches 65.
✅ Positive
- 📈 Low debt-to-equity ratio of 0.04.
- 📊 Increase in DII holding (+2.34%).
- 📉 Support near DMA 50 at 403 ₹ provides a potential entry zone.
⚠️ Limitation
- 📌 Extremely high P/E ratio of 283 vs industry average of 32.5.
- 📌 Very weak ROCE (1.92%) and ROE (1.24%).
- 📌 EPS of only 0.23 ₹, reflecting poor earnings strength.
📰 Company Negative News
- 📉 Quarterly PAT decline (111 Cr. → 67.3 Cr.).
- 📉 Weak profitability metrics compared to peers.
🌟 Company Positive News
- 📈 Increase in DII holding shows domestic investor confidence.
- 📈 Low leverage with debt-to-equity ratio of 0.04.
- 📈 Technical indicators (MACD, RSI) show mild bullishness.
🏭 Industry
- 💊 Biopharma industry benefits from healthcare demand and innovation.
- 📌 Industry P/E at 32.5, showing BIOCON trades at a significant premium.
📌 Conclusion
BIOCON is fundamentally weak with stretched valuations and poor profitability, making it a risky candidate for swing trading. Entry near 400–405 ₹ offers limited risk-reward, while exit near 430–440 ₹ is optimal. Traders should exercise caution and closely monitor earnings performance before entering positions.